Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (NASDAQ: LQDA) is a U.S.-based biopharmaceutical company committed to enhancing drug delivery and efficacy through its proprietary PRINT® technology. The company focuses on the development, manufacturing, and commercialization of innovative therapies for pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia’s flagship product, YUTREPIA™, is an investigational inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension (PAH) and PH-ILD. This product aims to improve exercise ability and quality of life for patients.
Liquidia is actively advancing its product pipeline, which includes L606, an investigational sustained-release formulation of treprostinil administered through a next-generation nebulizer. Currently, L606 is under evaluation in an open-label study and aims to extend drug exposure while minimizing local irritation in the lungs.
In addition to these developments, Liquidia has a valuable collaboration with leading pharmaceutical companies, leveraging its PRINT® technology for broader therapeutic areas. This technology enables precise production of uniform drug particles, enhancing safety and efficacy, and can be applied to various therapeutic areas and routes of administration.
Recent achievements include the promotion of key leadership within the company as they prepare for the potential FDA approval and launch of YUTREPIA. The company has also successfully navigated regulatory and legal challenges, ensuring a clear path for YUTREPIA’s market entry.
Financially, Liquidia has demonstrated robust growth, reporting significant revenue from its partnership with Sandoz for the commercial sale of Treprostinil Injection. The company has also secured substantial funding through strategic agreements, bolstering its cash reserves for continued research and development efforts.
Liquidia remains dedicated to transforming patient care by addressing unmet needs with innovative drug delivery solutions and is poised to make significant strides in the biopharmaceutical industry.
Liquidia Corporation has successfully completed its acquisition of RareGen, LLC, reinforcing its commitment to the pulmonary arterial hypertension (PAH) community. The all-stock merger, valued at 5,550,000 shares, positions Liquidia to enhance its offerings in the PAH market, particularly with the potential approval of LIQ861. The merger adds experienced board members Paul Manning and Roger Jeffs, signaling a strategic move towards growth. Liquidia Technologies stockholders will receive shares in the new Liquidia Corporation, which will trade under the ticker symbol 'LQDA' starting November 19, 2020.
Liquidia Technologies (NASDAQ: LQDA) has received stockholder approval for its merger with RareGen, LLC. The vote occurred on November 13, 2020, with approximately 71% of outstanding shares endorsing the Merger Agreement. This merger is anticipated to close on or about November 18, 2020. Post-merger, both companies will operate as wholly owned subsidiaries of Liquidia Corporation. Additionally, stockholders approved two plans for employee incentives effective upon merger completion.
Liquidia Technologies (Nasdaq: LQDA) announced that CEO Neal Fowler will present at the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020, at 7:55 PM GMT. The presentation will be available via a live audio webcast, with a replay accessible for at least 90 days. Liquidia is focused on developing innovative products using its proprietary PRINT® technology, particularly two candidates: LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain relief.
Liquidia Technologies (NASDAQ: LQDA) raised $75 million through a public offering, enhancing its balance sheet ahead of potential FDA approval for LIQ861, a novel treatment for pulmonary hypertension. The company reported a net loss of $15 million for Q3 2020, an increase from $13.4 million in Q3 2019. Liquidia bolstered its intellectual property position with a patent notice for LIQ861. The proposed merger with RareGen, LLC is set to improve customer reach and treatment options for patients. A conference call is scheduled for November 9, 2020.
Liquidia Technologies (NASDAQ: LQDA) announced the rescheduling of its special stockholder meeting to November 13, 2020. Initially set for October 21, the meeting will now be held virtually. The company recently received an unsolicited offer related to its LIQ861 product but determined it did not constitute a superior proposal, thus terminating discussions. The Board of Directors is urging stockholders to vote 'FOR' the proposals at the upcoming meeting, reaffirming their commitment to the planned merger with RareGen, LLC.
Liquidia Technologies (Nasdaq:LQDA) will report its third quarter 2020 financial results on November 6, 2020. A webcast and conference call to discuss these results is scheduled for November 9, 2020, at 8:00 a.m. ET. The company specializes in developing novel biopharmaceuticals using its proprietary PRINT® technology, focusing on two main product candidates: LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain. The event will allow investors to gain insights into the company's performance and future outlook.
Liquidia Technologies (Nasdaq:LQDA) announced it will report its third quarter 2020 financial results on November 6, 2020. A conference call and webcast will follow on November 9, 2020, at 8:00 a.m. ET to discuss these results and provide a corporate update. The company focuses on developing novel products using its proprietary PRINT® technology, particularly LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain management. This strategy underlines their commitment to improving patient outcomes through advanced therapies.
Liquidia Technologies has postponed its special stockholder meeting originally set for October 21, 2020, to evaluate an unsolicited offer for its LIQ861 product candidate. This offer is contingent upon terminating a previously arranged merger agreement. The company's board is assessing whether this offer qualifies as a 'Superior Proposal' as defined in the merger terms. Further information regarding the special meeting will be provided after the review concludes.
Liquidia Technologies (NASDAQ: LQDA) announced that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review of its patent claims against United Therapeutics' U.S. Patent No. 9,604,901 (‘901) regarding Tyvaso®. The PTAB declined the review for U.S. Patent No. 9,593,066 (‘066). CEO Neal Fowler emphasized the importance of this review for advancing LIQ861, a treatment for pulmonary arterial hypertension (PAH). LIQ861's New Drug Application is currently under review by the FDA, while a 30-month stay on approval relates to ongoing litigation with United Therapeutics.
Liquidia Technologies has appointed Dr. Gerald M. O’Brien as Vice President of Pulmonary Clinical Development, effective immediately. With 25 years of experience in pulmonary critical care, Dr. O’Brien aims to enhance Liquidia's efforts in treating pulmonary arterial hypertension (PAH). Previously, he led the PRIMEx trial at Complexa Inc. Liquidia focuses on developing innovative products using its proprietary PRINT® technology, specifically for PAH and post-operative pain management.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
What is Liquidia Corporation's primary focus?
What is YUTREPIA?
What is PRINT® technology?
What products are in Liquidia’s pipeline?
How does Liquidia generate revenue?
What recent leadership changes have occurred at Liquidia?
What is the current status of YUTREPIA’s FDA approval?
What are the financial highlights for Liquidia?
What legal challenges has Liquidia faced?
How can I learn more about Liquidia Corporation?
